STOK

Stoke Therapeutics, Inc. (STOK) - 10-K Summary

Business Context and Reporting Period

Company: Stoke Therapeutics, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Stoke is a late-stage clinical biopharmaceutical company developing RNA-based medicines using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform. The company focuses on upregulating protein expression to treat severe genetic diseases caused by haploinsufficiency. Its lead candidate, zorevunersen (STK-001), is in development for Dravet syndrome. A second candidate, STK-002, targets Autosomal Dominant Optic Atrophy (ADOA).

Key Financial Metrics (Year Ended Dec 31, 2024)

Note: Revenue is derived primarily from collaboration agreements (Acadia Pharmaceuticals) and does not include product sales, as the company has no approved products.

Material Changes vs. Prior Period

• Revenue Increase: Revenue increased 316% to $36.6 million, driven by a $17.9 million cumulative catch-up adjustment related to the Acadia collaboration agreement due to a revised estimate of total effort required.
• Net Loss Reduction: Net loss decreased by approximately $15.7 million compared to 2023, primarily due to higher revenue recognition and increased interest income ($12.6 million in 2024 vs. $9.9 million in 2023).
• R&D Expenses: Increased by $6.9 million, largely due to higher personnel costs ($4.7 million increase) and increased expenses for the zorevunersen program ($2.9 million increase), partially offset by a decrease in STK-002 (ADOA) program costs.
• Liquidity: Cash and marketable securities increased by $45.3 million, supported by $119.9 million in net proceeds from a follow-on public offering in April 2024 and $9.0 million from an at-the-market offering.

Guidance, Outlook, and Management Commentary

• Clinical Progress (Zorevunersen): The company announced alignment with the FDA, EMA, and PMDA on the design of the pivotal Phase 3 EMPEROR study for Dravet syndrome. The study is expected to initiate in Q2 2025, with data readout anticipated in H2 2027. Zorevunersen received Breakthrough Therapy Designation from the FDA in December 2024.
• Strategic Collaboration (Biogen): In February 2025 (subsequent to period end), Stoke entered a collaboration with Biogen for the development and commercialization of zorevunersen outside the U.S., Canada, and Mexico. This deal includes a $165 million upfront payment and up to $385 million in potential milestones.
• Liquidity Outlook: Management expects current cash resources ($246.7 million) combined with the Biogen upfront payment to fund operations through mid-2028.
• Leadership Transition: In March 2025, CEO Edward Kaye, M.D., stepped down. Ian F. Smith was appointed Interim CEO, and Arthur Tzianabos was appointed Interim Executive Chair.
• Risks: Key risks include the uncertainty of clinical trial outcomes, the ability to secure additional funding if needed, regulatory approval timelines, and the success of the Biogen collaboration.

Investor Verification Checklist

• Biogen Deal Terms: Verify the specific milestones and royalty rates in the February 2025 Biogen agreement and confirm the timing of the $165 million upfront payment receipt.
• Phase 3 EMPEROR Timeline: Monitor the actual initiation date of the Phase 3 study (targeted Q2 2025) and patient enrollment rates, as delays could impact the 2027 data readout.
• Cash Burn Rate: Track quarterly operating cash burn to validate the "mid-2028" runway estimate, especially given the upcoming costs of the Phase 3 trial.
• Acadia Revenue Recognition: Review future quarterly reports for the sustainability of revenue from the Acadia collaboration, noting the significant catch-up adjustment in 2024.
• Leadership Stability: Assess the impact of the CEO transition on strategic execution and the timeline for appointing a permanent CEO.